TG-MCB140160

NameTG-MCB140160
DescriptionDescription: RNA aptamers are small oligonucleotide molecules (~100 nucleotides) whose composition and resulting folded structure enable them to bind with high affinity and high selectivity to specific target ligands and therefore hold great promise as potential therapeutic drugs. The first aptamer to receive FDA approval was pegaptanib (Macugen), which is a treatment for wet age-related macular degeneration, a degenerative disease of the macula of the eye that leads to the loss of central vision. The pegaptanib aptamer acts by binding to and inhibiting the action of an isoform of vascular endothelial growth factor (VEGF), arresting degeneration. Functional aptamers are selected from a large, randomized initial library in a process known as SELEX (systematic evolution of ligands by exponential enrichment). This is an iterative process involving numerous rounds of binding, elution, and amplification against a specific target substrate. During each iteration - or round of selection - we enrich for the species with the highest binding affinity to the target. After multiple rounds, we ideally have an enriched aptamer library suitable for subsequent investigation. Modern techniques employ massively parallel sequencing, enabling the generation of large libraries (~10^{6} sequences) in a matter of hours for each round of selection. As RNA is single-stranded, the covariance model (CM) approach (Eddy, SR, Durbin, R (1994). RNA sequence analysis using covariance models. Nucleic Acids Res., 22, 11:2079-88) are ideal for representing motifs in their secondary structures, allowing us to discover patterns within functional aptamer populations following each round. CMs have been implemented in 'Infernal' (http://infernal.janelia.org) a program that infers RNA alignments based on RNA sequence and structure. Calibrating a single CM in Infernal however can take several hours and is a significant performance bottleneck for our work. However, as each CM calculation is itself independently determined and requires defined pr! ocessing and memory resources, their computation in parallel using the Open Science Grid offers a potential solution to this problem. Using part of a Campus Champion award to our institution, we have prototyped such a solution by making use of the Simple API for Grid Applications (SAGA) to interface with OSG and manage job submissions and file transfers. When run in parallel, our results showed a significant speed up, constrained by typical latencies and QoS associated with nominal OSG usage. This prior study demonstrated the feasibility of using SAGA and the OSG to support the parallelization of CM analysis of such large scale sequence based aptamer libraries, and forms the basis of this startup allocation request to further constrain workflow productivity and support the PhD research of Mr. Kevin Shieh.
OrganizationAlbert Einstein College of Medicine
DepartmentGenetics
Sponsor Campus GridOSG-XSEDE
Principal Investigator
David Rhee
Field Of ScienceMolecular and Structural Biosciences
DisableFalse